Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study
The aim of this study was to explore the pharmacokinetics of the two main active compounds (THC and CBD) contained in the cannabis oil extract Bedrocan® in fasting and fed dogs. Bedrocan® (20% delta-9-tetrahydrocannabinol [THC] and 0.5% cannabidiol [CBD]) was administered at 1.5 and 0.037 mg/kg THC...
Gespeichert in:
| Veröffentlicht in: | Research in veterinary science 2019-04, Vol.123, p.26-28 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28 |
|---|---|
| container_issue | |
| container_start_page | 26 |
| container_title | Research in veterinary science |
| container_volume | 123 |
| creator | Łebkowska-Wieruszewska, Beata Stefanelli, Fabio Chericoni, Silvio Owen, Helen Poapolathep, Amnart Lisowski, Andrzej Giorgi, Mario |
| description | The aim of this study was to explore the pharmacokinetics of the two main active compounds (THC and CBD) contained in the cannabis oil extract Bedrocan® in fasting and fed dogs. Bedrocan® (20% delta-9-tetrahydrocannabinol [THC] and 0.5% cannabidiol [CBD]) was administered at 1.5 and 0.037 mg/kg THC and CBD, respectively in fasted and fed dogs according to a 2 × 2 cross over study design. The quantification of the two active ingredients was performed by LC/MS. No detectable concentrations of CDB were found at any collection time. THC was quantifiable from 0.5 to 10 h, although there was large inter-subject variability. Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ng/mL) compared with the fasted group. A larger AUC was found in the fasted group; the relative oral bioavailability in fed animals was 48.22%.
[Display omitted]
•The fed status increased Tmax and reduced Cmax of THC in dogs•The relative oral bioavailability of THC in fed dogs was around 50%•THC blood concentrations in dogs are consistent to those reported in humans |
| doi_str_mv | 10.1016/j.rvsc.2018.12.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2191978969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0034528818313158</els_id><sourcerecordid>2191978969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-a1d195172545c313fbe1ec159b4cfcbf5c829b87d85d2b9622f0f426354e1e463</originalsourceid><addsrcrecordid>eNp9kM9uVCEUh4mxsWP1BVwYEre9Vw5c7nCNm7bxX9KkXeiacOFQGWdgBGZiX6oP4ZPJZKpLVxD4fr-T8xHyClgPDMa3qz7vi-05A9UD7xkTT8gCpOAdH0d4ShbtZegkV-qUPC9lxRgbAJbPyKlgUjEu-ILg7XeTN8amHyFiDbbQ5Oklupysib8fzqmh7RLNHNpPWFP8VbOx9ZyGSL0pNcQ7aqKjHh116a68oxexQdt1yqaGPdJSd-7-BTnxZl3w5eN5Rr59_PD16nN3ffPpy9XFdWeFGmpnwMEkYcnlIK0A4WcEtCCnebDezl5axadZLZ2Sjs_TyLlnfuCjkEMDh1GckTfH3m1OP3dYql6lXY5tpOYwwbRU0zg1ih8pm1MpGb3e5rAx-V4D0wezeqUPZvXBrAaum8cWev1YvZs36P5F_qpswPsjgG3BfcCsiw0YLbqQ0VbtUvhf_x8_pYo9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2191978969</pqid></control><display><type>article</type><title>Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study</title><source>Elsevier ScienceDirect Journals</source><creator>Łebkowska-Wieruszewska, Beata ; Stefanelli, Fabio ; Chericoni, Silvio ; Owen, Helen ; Poapolathep, Amnart ; Lisowski, Andrzej ; Giorgi, Mario</creator><creatorcontrib>Łebkowska-Wieruszewska, Beata ; Stefanelli, Fabio ; Chericoni, Silvio ; Owen, Helen ; Poapolathep, Amnart ; Lisowski, Andrzej ; Giorgi, Mario</creatorcontrib><description>The aim of this study was to explore the pharmacokinetics of the two main active compounds (THC and CBD) contained in the cannabis oil extract Bedrocan® in fasting and fed dogs. Bedrocan® (20% delta-9-tetrahydrocannabinol [THC] and 0.5% cannabidiol [CBD]) was administered at 1.5 and 0.037 mg/kg THC and CBD, respectively in fasted and fed dogs according to a 2 × 2 cross over study design. The quantification of the two active ingredients was performed by LC/MS. No detectable concentrations of CDB were found at any collection time. THC was quantifiable from 0.5 to 10 h, although there was large inter-subject variability. Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ng/mL) compared with the fasted group. A larger AUC was found in the fasted group; the relative oral bioavailability in fed animals was 48.22%.
[Display omitted]
•The fed status increased Tmax and reduced Cmax of THC in dogs•The relative oral bioavailability of THC in fed dogs was around 50%•THC blood concentrations in dogs are consistent to those reported in humans</description><identifier>ISSN: 0034-5288</identifier><identifier>EISSN: 1532-2661</identifier><identifier>DOI: 10.1016/j.rvsc.2018.12.003</identifier><identifier>PMID: 30580232</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Bedrocan ; Bioavailability ; Blood levels ; Cannabinoids ; Cannabis ; Cannabis oil extract ; Dogs ; Fasting ; Food ; Medical marijuana ; Metabolites ; Pain ; Pharmacokinetics ; Pharmacology ; Studies ; Tetrahydrocannabinol ; Veterinary medicine</subject><ispartof>Research in veterinary science, 2019-04, Vol.123, p.26-28</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Apr 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-a1d195172545c313fbe1ec159b4cfcbf5c829b87d85d2b9622f0f426354e1e463</citedby><cites>FETCH-LOGICAL-c384t-a1d195172545c313fbe1ec159b4cfcbf5c829b87d85d2b9622f0f426354e1e463</cites><orcidid>0000-0002-1569-0599 ; 0000-0003-3657-4703</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0034528818313158$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30580232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Łebkowska-Wieruszewska, Beata</creatorcontrib><creatorcontrib>Stefanelli, Fabio</creatorcontrib><creatorcontrib>Chericoni, Silvio</creatorcontrib><creatorcontrib>Owen, Helen</creatorcontrib><creatorcontrib>Poapolathep, Amnart</creatorcontrib><creatorcontrib>Lisowski, Andrzej</creatorcontrib><creatorcontrib>Giorgi, Mario</creatorcontrib><title>Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study</title><title>Research in veterinary science</title><addtitle>Res Vet Sci</addtitle><description>The aim of this study was to explore the pharmacokinetics of the two main active compounds (THC and CBD) contained in the cannabis oil extract Bedrocan® in fasting and fed dogs. Bedrocan® (20% delta-9-tetrahydrocannabinol [THC] and 0.5% cannabidiol [CBD]) was administered at 1.5 and 0.037 mg/kg THC and CBD, respectively in fasted and fed dogs according to a 2 × 2 cross over study design. The quantification of the two active ingredients was performed by LC/MS. No detectable concentrations of CDB were found at any collection time. THC was quantifiable from 0.5 to 10 h, although there was large inter-subject variability. Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ng/mL) compared with the fasted group. A larger AUC was found in the fasted group; the relative oral bioavailability in fed animals was 48.22%.
[Display omitted]
•The fed status increased Tmax and reduced Cmax of THC in dogs•The relative oral bioavailability of THC in fed dogs was around 50%•THC blood concentrations in dogs are consistent to those reported in humans</description><subject>Bedrocan</subject><subject>Bioavailability</subject><subject>Blood levels</subject><subject>Cannabinoids</subject><subject>Cannabis</subject><subject>Cannabis oil extract</subject><subject>Dogs</subject><subject>Fasting</subject><subject>Food</subject><subject>Medical marijuana</subject><subject>Metabolites</subject><subject>Pain</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Studies</subject><subject>Tetrahydrocannabinol</subject><subject>Veterinary medicine</subject><issn>0034-5288</issn><issn>1532-2661</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kM9uVCEUh4mxsWP1BVwYEre9Vw5c7nCNm7bxX9KkXeiacOFQGWdgBGZiX6oP4ZPJZKpLVxD4fr-T8xHyClgPDMa3qz7vi-05A9UD7xkTT8gCpOAdH0d4ShbtZegkV-qUPC9lxRgbAJbPyKlgUjEu-ILg7XeTN8amHyFiDbbQ5Oklupysib8fzqmh7RLNHNpPWFP8VbOx9ZyGSL0pNcQ7aqKjHh116a68oxexQdt1yqaGPdJSd-7-BTnxZl3w5eN5Rr59_PD16nN3ffPpy9XFdWeFGmpnwMEkYcnlIK0A4WcEtCCnebDezl5axadZLZ2Sjs_TyLlnfuCjkEMDh1GckTfH3m1OP3dYql6lXY5tpOYwwbRU0zg1ih8pm1MpGb3e5rAx-V4D0wezeqUPZvXBrAaum8cWev1YvZs36P5F_qpswPsjgG3BfcCsiw0YLbqQ0VbtUvhf_x8_pYo9</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Łebkowska-Wieruszewska, Beata</creator><creator>Stefanelli, Fabio</creator><creator>Chericoni, Silvio</creator><creator>Owen, Helen</creator><creator>Poapolathep, Amnart</creator><creator>Lisowski, Andrzej</creator><creator>Giorgi, Mario</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-1569-0599</orcidid><orcidid>https://orcid.org/0000-0003-3657-4703</orcidid></search><sort><creationdate>20190401</creationdate><title>Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study</title><author>Łebkowska-Wieruszewska, Beata ; Stefanelli, Fabio ; Chericoni, Silvio ; Owen, Helen ; Poapolathep, Amnart ; Lisowski, Andrzej ; Giorgi, Mario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-a1d195172545c313fbe1ec159b4cfcbf5c829b87d85d2b9622f0f426354e1e463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bedrocan</topic><topic>Bioavailability</topic><topic>Blood levels</topic><topic>Cannabinoids</topic><topic>Cannabis</topic><topic>Cannabis oil extract</topic><topic>Dogs</topic><topic>Fasting</topic><topic>Food</topic><topic>Medical marijuana</topic><topic>Metabolites</topic><topic>Pain</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Studies</topic><topic>Tetrahydrocannabinol</topic><topic>Veterinary medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Łebkowska-Wieruszewska, Beata</creatorcontrib><creatorcontrib>Stefanelli, Fabio</creatorcontrib><creatorcontrib>Chericoni, Silvio</creatorcontrib><creatorcontrib>Owen, Helen</creatorcontrib><creatorcontrib>Poapolathep, Amnart</creatorcontrib><creatorcontrib>Lisowski, Andrzej</creatorcontrib><creatorcontrib>Giorgi, Mario</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Research in veterinary science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Łebkowska-Wieruszewska, Beata</au><au>Stefanelli, Fabio</au><au>Chericoni, Silvio</au><au>Owen, Helen</au><au>Poapolathep, Amnart</au><au>Lisowski, Andrzej</au><au>Giorgi, Mario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study</atitle><jtitle>Research in veterinary science</jtitle><addtitle>Res Vet Sci</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>123</volume><spage>26</spage><epage>28</epage><pages>26-28</pages><issn>0034-5288</issn><eissn>1532-2661</eissn><abstract>The aim of this study was to explore the pharmacokinetics of the two main active compounds (THC and CBD) contained in the cannabis oil extract Bedrocan® in fasting and fed dogs. Bedrocan® (20% delta-9-tetrahydrocannabinol [THC] and 0.5% cannabidiol [CBD]) was administered at 1.5 and 0.037 mg/kg THC and CBD, respectively in fasted and fed dogs according to a 2 × 2 cross over study design. The quantification of the two active ingredients was performed by LC/MS. No detectable concentrations of CDB were found at any collection time. THC was quantifiable from 0.5 to 10 h, although there was large inter-subject variability. Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ng/mL) compared with the fasted group. A larger AUC was found in the fasted group; the relative oral bioavailability in fed animals was 48.22%.
[Display omitted]
•The fed status increased Tmax and reduced Cmax of THC in dogs•The relative oral bioavailability of THC in fed dogs was around 50%•THC blood concentrations in dogs are consistent to those reported in humans</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30580232</pmid><doi>10.1016/j.rvsc.2018.12.003</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-1569-0599</orcidid><orcidid>https://orcid.org/0000-0003-3657-4703</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0034-5288 |
| ispartof | Research in veterinary science, 2019-04, Vol.123, p.26-28 |
| issn | 0034-5288 1532-2661 |
| language | eng |
| recordid | cdi_proquest_journals_2191978969 |
| source | Elsevier ScienceDirect Journals |
| subjects | Bedrocan Bioavailability Blood levels Cannabinoids Cannabis Cannabis oil extract Dogs Fasting Food Medical marijuana Metabolites Pain Pharmacokinetics Pharmacology Studies Tetrahydrocannabinol Veterinary medicine |
| title | Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T22%3A52%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20Bedrocan%C2%AE,%20a%20cannabis%20oil%20extract,%20in%20fasting%20and%20fed%20dogs:%20An%20explorative%20study&rft.jtitle=Research%20in%20veterinary%20science&rft.au=%C5%81ebkowska-Wieruszewska,%20Beata&rft.date=2019-04-01&rft.volume=123&rft.spage=26&rft.epage=28&rft.pages=26-28&rft.issn=0034-5288&rft.eissn=1532-2661&rft_id=info:doi/10.1016/j.rvsc.2018.12.003&rft_dat=%3Cproquest_cross%3E2191978969%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2191978969&rft_id=info:pmid/30580232&rft_els_id=S0034528818313158&rfr_iscdi=true |